Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells - 11/02/17
, Valentina Coccè b, g, 1, Carla Masia b, g, Martina Milani c, Emanuela Omodeo Salè c, Giulio Alessandri d, Eugenio Parati d, Francesca Sisto b, g, Francesca Pentimalli e, Anna T. Brini b, g, Augusto Pessina b, g, 2, Lorenzo Spaggiari a, f, 2Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Introduction |
Malignant pleural mesothelioma (MPM) is a rare fatal asbestos-related malignancy originating in the mesothelial cells of the pleura. A platinum-based doublet containing a third-generation antifolate is the front-line standard of care whilst there are no approved second-line treatments for MPM which remains a disease setting to test the efficacy of new therapeutic agents.
Methods |
Bone marrow mesenchymal stromal cells (BM-MSCs) were loaded with pemetrexed (PMX) and paclitaxel (PTX) according to a standardized procedure. Drug release by both PMX- and PTX-primed BM-MSCs (BM-MSCs/PMX and BM-MSCs/PTX) was tested on the in vitro proliferation of a panel of tumor cell lines including NCI-H28 mesothelioma.
Results |
The in vitro anticancer activity of pure PTX was significantly higher than that of PMX against all the cell lines tested (14.7 times higher than that of PMX against NCI-H28). Whereas BM-MSCs did not take up and release PMX in amounts effective on mesothelioma, PTX-loaded BM-MSCs dramatically inhibited mesothelioma proliferation.
Conclusions |
PTX-primed mesenchymal stromal cells successfully inhibit the in vitro proliferation of human mesothelioma cells. Further studies and in vivo testing are required to confirm our preliminary in vitro results as a potential new mesothelioma therapy based on cell drug delivery.
Le texte complet de cet article est disponible en PDF.Keywords : Mesenchymal stromal cells, Mesothelioma, Paclitaxel, Pemetrexed, Cell drug delivery
Plan
Vol 87
P. 755-758 - mars 2017 Retour au numéro
Article précédent
- Novel phyto-derivative BRM270 inhibits hepatocellular carcinoma cells proliferation by inducing G2/M phase cell cycle arrest and apoptosis in xenograft mice model
- Raj Kumar Mongre, Neelesh Sharma, Simrinder Singh Sodhi, Mrinmoy Ghosh, Amit Kumar Singh, Nameun Kim, Yang Ho Park, Young Gyu Shin, Sung Jin Kim, Zhang Jiao Jiao, Do Luong Huynh, Dong Kee Jeong
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?